P53 and PET羊elated parameters as a prognostic factor of head and neck carcinoma treated by chemoradiation

• Project/Area Number: 21592193
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Otorhinolaryngology
• Research Institution: Osaka University
• Principal Investigator: INOHARA Hidenori 大阪大学, 医学系研究科, 教授 (00273657)
• Project Period (FY): 2009 – 2011
• Project Status: Completed (Fiscal Year 2011)
• Budget Amount: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000); Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
• Keywords: 頭頸部扁平上皮癌 / 化学放射線同時併用療法 / p53コドン72遺伝子多型 / p53遺伝子変異 / ヒトパピローマウイルス / SUVmax / SUVmean / metabolic tumor volume / 頭頸部癌 / 科学放射線同時併用療法

Research Abstract

Prognostic significance of p53 codon72 polymorphism, p503 mutations. human papillomavirus, and pretreatment PET parameters, in addition to clinical factors, were prospectively addressed in patients with locoreginally advanced head and neck sqamous cell carcinoma treated by concurrent chemoradiotherapy. Pretreatment PET parameters include SUVmax. SUVmean, and metabolic tumor volume of a primary tumor. Multivariatc analysis revealed that MTV is only an independent prognostic factor. Overall survival as well as laryngectomy survival were significantly better in patients with low MTV tumor than in those with high MTV tumor.

Research Products

• [Presentation] 頭頸部診療癌におけるPETの有用性 (2011)
  • Author(s): 猪原秀典
  • Organizer: 第113回日本耳鼻咽喉科学会総会・学術講演会ランチョンセイナー1
  • Place of Presentation: 新潟
  • Year and Date: 2011-05-10